Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2

Fig. 3

Correlation between MALAT1 and EZH2 in MCL. a–d RNA immunoprecipitation in Mino and Jeko-1 cells. a Input and immunoprecipitate from rabbit IgG and anti-EZH2 antibody bond beads, detected by immunoblotting with EZH2 antibody, b Input and immunoprecipitate from rabbit IgG and anti-SUZ12 antibody bound beads, detected by immunoblotting with SUZ12 antibody, using Western blot analysis. c, d qPCR showing MALAT1 is significantly enriched in the immunoprecipitate from the EZH2 antibody bound beads compared to SUZ12 and IgG (control antibody) in (c) Mino and (d) Jeko-1 cells. e Pearson’s correlation between MALAT1 mRNA and EZH2 mRNA expression (2−delta Ct value) in MCL. f Relative MALAT1 expression in MCL clinical samples and CD19 + B lymphocyte from healthy donors, measured by qRT-PCR and normalized to gene expression levels of GAPDH. g Overall survival of MCL patients with high and low EZH2 expression (Kaplan–Meier plot). Patients with high EZH2 expression levels (n = 20) had significantly lower overall survival than those with low expression (n = 20). Hazard ratio: 3.977 (95% CI: 1.512 to 13.01). Data represent the mean ± SD.**P < 0.01

Back to article page